Michael Broyles PharmD

Michael Broyles, PharmD, holds degrees and a doctorate from the University of Missouri-Kansas City School of Pharmacy and the University of Arkansas for Medical Sciences. Dr. Broyles has more than 30 years of experience as a hospital pharmacy director and laboratory director. He has served as Chairman of pharmacy initiatives for one of the nation’s largest hospital networks for two decades. He has engaged in pharmacy initiatives and antimicrobial stewardship consulting for 23 of 40 of the nation’s top integrated networks and consulted for hospitals. He is a second adopter of procalcitonin for the management of antibiotic therapy in sepsis, LRTI, and other infections in the United States, having viewed more than 70,000 determinations. He has performed extensive advanced analytics on the performance and value of PCT in most bacterial conditions.

Dr. Broyles participated in the FDA approval process for the use of PCT in sepsis and lower respiratory tract infections. He recently served on the Global Expert Consensus Panel for the use of procalcitonin guidance to optimize its use in bacterial infections. He also serves as Medscape Faculty for Biomarkers and Infectious Diseases and on the Arkansas Department of Health Epidemiology and Antimicrobial Stewardship committees.